Dynamic Technology Lab Private Ltd Decreases Holdings in Novo Nordisk A/S $NVO

Dynamic Technology Lab Private Ltd reduced its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 65.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,662 shares of the company's stock after selling 12,684 shares during the period. Dynamic Technology Lab Private Ltd's holdings in Novo Nordisk A/S were worth $463,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. Revolve Wealth Partners LLC grew its stake in shares of Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock valued at $214,000 after purchasing an additional 200 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Novo Nordisk A/S by 3.2% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 95,080 shares of the company's stock valued at $8,179,000 after buying an additional 2,920 shares during the period. Nuveen Asset Management LLC increased its holdings in Novo Nordisk A/S by 73.2% during the fourth quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company's stock valued at $537,189,000 after buying an additional 2,639,693 shares during the last quarter. Nia Impact Advisors LLC increased its holdings in Novo Nordisk A/S by 1.8% during the fourth quarter. Nia Impact Advisors LLC now owns 23,200 shares of the company's stock valued at $1,996,000 after buying an additional 415 shares during the last quarter. Finally, Quantinno Capital Management LP raised its position in Novo Nordisk A/S by 4.9% in the fourth quarter. Quantinno Capital Management LP now owns 211,866 shares of the company's stock worth $18,225,000 after acquiring an additional 9,885 shares during the period. Hedge funds and other institutional investors own 11.54% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on NVO. Wall Street Zen downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. BNP Paribas Exane upgraded Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 price target for the company in a research report on Wednesday, August 13th. UBS Group downgraded Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research note on Tuesday, August 5th. Sanford C. Bernstein upgraded Novo Nordisk A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday. Finally, Zacks Research lowered shares of Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a report on Wednesday, August 20th. Four research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Novo Nordisk A/S currently has a consensus rating of "Hold" and an average price target of $81.00.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $54.36 on Thursday. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a twelve month low of $45.05 and a twelve month high of $138.22. The business has a 50-day moving average price of $58.54 and a 200-day moving average price of $66.99. The firm has a market cap of $242.70 billion, a price-to-earnings ratio of 14.93, a price-to-earnings-growth ratio of 2.06 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, topping analysts' consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The company had revenue of $11.69 billion for the quarter, compared to analysts' expectations of $77.51 billion. As a group, equities research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were issued a $0.4119 dividend. This represents a dividend yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S's payout ratio is 22.53%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.